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Abstract
Background: In low-incidence countries, most tuberculosis (TB) cases occur among migrants and are caused by
reactivation of latent tuberculosis infection (LTBI) acquired in the country of origin. Diagnosis and treatment of LTBI
are rarely implemented to reduce the burden of TB in immigrants, partly because the cost-effectiveness profile of
this intervention is uncertain.
The objective of this research is to perform a review of the literature to assess the cost-effectiveness of LTBI
diagnosis and treatment strategies in migrants.
Methods: Scoping review of economic evaluations on LTBI screening strategies for migrants was carried out in
Medline.
Results: Nine studies met the inclusion criteria. LTBI screening was cost-effective according to seven studies.
Findings of four studies support interferon gamma release assay as the most cost-effective test for LTBI screening in
migrants. Two studies found that LTBI screening is cost-effective only if carried out in immigrants who are contacts
of active TB cases.
Discussion and Conclusions: Our findings support the cost-effectiveness of LTBI diagnostic and treatment
strategies in migrants especially if they are focused on young subjects from high incidence countries. These
strategies could represent and adjunctive and synergistic tool to achieve the ambitious aim of TB elimination.
Background
In low incidence countries, the majority of the cases of
active tuberculosis (TB) occur among migrants from high
incidence countries [1]. In this setting migrants can
develop TB following three main mechanisms [2]:
1. TB can already be present at the time they enter in
the host country;
2. TB can be the consequence of the reactivation of
latent tuberculosis infection (LTBI) acquired in the
country of origin, occurring months to years after the
settlement in the host country [3, 4];
3. Primary progressive TB can follow a new infection
acquired in the host country [4, 5] or during a return
travel to the country of origin [6].
Most countries with low TB incidence adopt TB scree-
ning policies for migrants from high TB incidence
countries. The majority of countries screen migrants for
active TB through chest x-ray (CXR) before or soon after
arrival, while screening for LTBI is not consistently imple
mented [7]. Screening protocols that include CXR as first
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step are able to identify the majority of migrants with
active TB at entry and, occasionally, migrants with radio-
logical alterations suggestive of LTBI. However, most
persons with LTBI go undetected as a diagnostic test for
this condition is not usually applied. Epidemiological
studies based on molecular techniques to genotype
the M. tuberculosis isolates showed that 55–90 % of
TB cases diagnosed in foreign born patients are due
to LTBI reactivation [8, 9].
Screening migrants for LTBI and providing treatment to
those with this condition is a plausible strategy to prevent
the disease and reduce the risk of spread infection in the
native population [10, 11]. Diagnosis and treatment of
LTBI was recommended in Europe already more than ten
years ago [12, 13], and is now included among the main
interventions of the new global post-2015 strategy for TB
control [13].
Only 16 of 29 industrialized countries belonging to the
Organization for Economic Co-operation and Develop-
ment, screen immigrants for LTBI, most frequently post-
arrival in the host country [7].
In 11 of these 16 countries, the screening is compulsory
for legal migrants. Children and young adults (<40 years)
are most commonly targeted for LTBI screening. The
most common test used for screening is Tuberculin Skin
Test (TST), used in 11 out of 16 countries. Patients and
physicians compliance to the LTBI screening protocol is
essential for the effectiveness [10], but it is reported to be
low [11].
Appropriate information on cost-effectiveness of LTBI
screening strategies may help the policy makers to decide
appropriate interventions. Thus, we performed a review of
published economic evaluations (EE) of different LTBI
screening strategies.
Methods
Ethical approval was not required for this review study.
Inclusion criteria
In this review we included studies with all the three
following criteria: 1) had migrants as study target popu-
lation; 2) included diagnosis and treatment for LTBI; 3)
reported findings of EE analyses. Both model-based EEs
and those alongside clinical trials (or in combinations as
well) were included.
Search strategy
MEDLINE and the Cochrane Library electronic data-
bases were searched for studies published up to July
2014. The terms used for the search strategy were: (latent
tuberculosis OR LTBI OR “latent tuberculosis”[Mesh])
AND (screening OR Mantoux OR IGRA OR “mass screen-
ing”[Mesh] OR “tuberculin test”[Mesh] OR “Interferon-
gamma Release Tests”[Mesh]) AND (cost-effect* OR
cost-bene* OR “Cost- Benefit Analysis”[Mesh]). No lan-
guage restriction was done. The search was performed
also using the term “latent tuberculosis screening in mi-
grants” as free text.
Data extraction and assessment
All references retrieved were collected using the EndNote®,
version X5 (Thomson Reuter) program. Identified titles
and abstracts were screened for their eligibility for inclu-
sion and the full text of potentially relevant studies was
obtained and examined. Two review authors (LZ, GC)
independently screened titles and abstracts of each
study. Based on the full text revision, the two reviewers
independently selected the studies, and inter-reviewer
disagreement was solved by discussion. The following
information was extracted: setting, study design, partici-
pants, EEs data, including type of EE, screening alterna-
tives, cost description, analysis perspective, source of
data (literature, clinical studies), modeling (if any, in-
cluding time horizon and discount rate), key results and
authors’ conclusions. The following data were collected
for clinical trials used for EE analyses: inclusion criteria,
study participants, setting, design and methods, results
and authors’ conclusions. Agreement on inclusion was
calculated using the Kappa statistics.
Study quality was assessed using an established check-
list of criteria for assessing the quality of economic eval-
uations in health care [14]. This tool includes ten items
regarding cost effectiveness analysis: the presence of a
clearly stated hypothesis and comparator; the used
methods; the medical evidence; appropriate costs and
benefits considered; a marginal analysis and a sensitivity
analysis have been undertaken; the analysis was appro-
priate to the local environment.
Results
Search results
The literature search resulted in 109 titles. A total of 86
duplicates or non-pertinent or non-appropriate refer-
ences were deleted, resulting in 23 potentially relevant
studies. Reviewers agreed on 18 of 23 papers (78.3 %) se-
lected for reliability check (K = 0.697), and disagree-
ments were resolved by consensus. Ten of 23 papers
(43.5 %) met inclusion criteria and were therefore in-
cluded in the final step of review (Fig. 1).
General characteristics of included studies
The 10 research studies included in the review (Table 1)
were published in 8 journals, 2 in the Am J Respir Crit
Care Med and Thorax, and the others in 6 different
journals. The distribution of papers per year of publica-
tion ranged from 2000 to 2014.
Four studies were performed in the US, 3 in the United
Kingdom, and 3 in Canada.
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In four studies age limitations in the study population
were used: children 4 to 18 years old [17], migrants
>16 year old (median 29 years) [16], migrants or foreign
born subjects > 18 year old [18], and migrants aging
<35 years [15].
Four studies considered immigrants at the moment of
their entrance or application for residence permission
[11, 18–20]. Two studies referred to “new immigrants”
or foreign born subjects without further specification
[17, 21, 22]. Two studies referred to immigrants arrived
within 5 years [7, 15]. One study considered both recent
migrants and foreign born residents in US for more than
5 years [23].
In 5 studies the screening was carried out according to
TB incidence in the country of origin regardless of age
[11, 17, 19, 20, 23], whereas 3 studies compared the
cost-effectiveness of screening migrants with different
thresholds of TB incidence in the country of origin
[14, 16, 21]. One study considered migrants from all
developing countries [18].
Several LTBI diagnostic strategies (screening with CXR
and follow-up of inactive TB, screening with TST, screening
with TST followed by confirmation with Interferon gamma
release assay - IGRA, screening with single step IGRA)
were compared with each other and/or with different non-
LTBI screening strategies including no screening, screening
for active TB with CXR, and close-contact investigation
(Table 1). Isoniazid for 6–9 months was the LTBI treatment
regimen used in the majority of studies [11, 17, 19, 20, 22,
23], in one study isoniazid plus rifampicin for 3 months
was used [16], in one study either isoniazid for 6 months or
isoniazid plus rifampicin for 3 months were used [15], and
in one study different LTBI treatment regimens (isoniazid
for 9 months, rifampicin for 4 months, rifampicin plus pyr-
azinamide for 2 months) were compared [18]. In one study
the LTBI treatment regimen was not specified [21].
Fig. 1 Flow diagram showing the number of papers identified by the search and the selection process
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Table 1 Economic evaluations of latent tuberculosis infection screenings published up to July 2014
Author
(Country; Year)
Alternatives Data source EE
Type
Perspective Model
Horizon
Discount
rate
Cost Cost description Differential Costs ICER Conclusion
Dasgupta et al.
(Canada; 2000)
[19]
1. Screening (medical
evaluation, CXR);
Administrative
data bases
CEA Health care
payer
Markov
20 years
Direct CXR, clinic visits,
investigations,
hospitalization,
drugs, physicians’ and
pharmacists’ fees,
administrative
activities.
• TB case detected:
CAN$ 31,418;
prevented:
CAN$ 73,125;
Close-contact
investigation was highly
cost-effective and
resulted in net savings.
Immigrant applicant
screening and
surveillance programs
had a significant impact
but were much less
cost-effective, in large
part because of
substantial operational
problems. Radiographic
screening of newly
arriving foreign-born
populations for TB
could be cost-effective
and have considerable
individual and public
health benefits.
• CAN$ 55,728;
CAN$ 155,729;
2. Surveillance of inactive
TB, including LTBI
treatment;
• CAN$ 10,275;
CAN$ 29,668.
3. Close-contact
investigation
Khan et al.
(USA; 2002)
[18]
1. No LTBI screening; Data bases CEA,
CUA
Societal Markov
Lifetime
3.00%
Health
Direct
Transportation,
ambulatory care,
services of
interpreters,
laboratory tests,
medications, adverse
drug reactions,
hospitalization, and
patients’ time.
Total savings: US$60
to US$90 million,
assuming to avert
9–10 thousand TB
infections per year.
CEA Results variable
according to country
of origin.• TST followed by INH:
savings or dominated,
depending on regions.
2. TST followed by INH;
Indirect A strategy of
detecting and
treating LTBI was
cost-saving among
immigrants from
Mexico, Haiti, sub-
Saharan Africa, South
Asia, and developing
nations in East Asia
and the Pacific.
• TST followed RIF:
dominant.
4. TST followed by RIF
plus PZM.
• TST followed RIF plus
PZM: saving or cost/
effective (US$2,551 -
US$149,978 per future
case averted),
depending on regions.
3. TST followed by RIF;
per QALY Screening was highly
cost-effective among
immigrants from
other developing
nations. RIF-PZM was
the preferred
treatment for treating
LTBI in immigrants
from Vietnam, Haiti,
and the Philippines.
• TST followed by INH:
savings, US$914 -
US$5,952, or dominated
depending on regions.
• TST followed by RIF:
dominant.
• TST followed by RIF
plus PZM: savings, or
US$1,276 - US$53,388,
depending on regions.
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Table 1 Economic evaluations of latent tuberculosis infection screenings published up to July 2014 (Continued)
Brassard et al.
(Canada; 2006)
[17]
1. LTBI school-screening
program in newly arrived
immigrant children (TST
followed by INH);
Clinical trialc CBA Health care
payer
No Health
Direct
Total material and
labor costs associated
with the school-
screening program
and the associate
investigations for
children and
associates.
Total savings:
CAN$ 363,923.
The school-based
LTBI-screening
program was found
to be cost-effective.Without associate
investigation:
CAN$ 268,393. Savings were mainly
due to hospitalization
costs.
2. Active TB
management through
passive case finding.
Porco et al.
(USA; 2006)
[20]
1. Follow-up of TB-
notification patients,
including LTBI treatment
for latently infected
individuals;
Published
literature,
administrative
data bases
CEA,
CUA
Health care
payer
Markov
20 years
3.00%
Direct Diagnostic tests,
nursing assessments
and doctor visits,
drugs, side effects,
hospitalizations.
The program yielded
7.7 net QALYs, US$
25,000 in net savings,
and prevented 4
cases of TB.
Treatment of TB4s
was cost-saving.
Domestic follow up is
highly cost-effective
as early detection and
treatment reduces the
rate of hospitalization.
Treatment of TB2s
was highly cost-
effective: US$4,400
per QALY and
US$4,700 per case
prevented.
2. No follow-up.
Oxlade O et al.
(Canada;2007)
[11]
1. CXR; Published
literature,
administrative
data bases
CEA Societal Markov Health
Direct
All government and
health system costs,
patients’ out-of-
pocket expenditures,
but not TB-related
death or disability.
Savings only in
high-very high risk
populations:
CXR - the least costly
ICER per case
prevented: CAN$ 875
for immigrants from
high-incidence TB up
to CAN$ 2.2 million
from low incidence.
Screening with CXR
would be the most
and QFT the least
cost-effective.
2. TST; 20 years
3. QFT; 3.00%
4. TST+QTF; • CXR - CAN$ 44,710;
CAN$ 65,490;
Screening for LTBI, with
TST or QFT, is cost-
effective only if the risk
of disease is high. The
most cost-effective use
of QFT is to test TST-
positive persons.
5. No screening.
QFT - the most
expensive:
CAN$62,643 up to
CAN$1,122,200.
• TST - CAN$ 136260;
CAN$ 476320;
TST - better than QFT
with saving up to
CAN$35,000
compared to QFT, but
in populations BCG-
vaccinated after
infancy, where TST
more expensive
because of low
specificity.
Three scenarios:
• QFT - CAN$ 100,490;
CAN$ 440,550.
Screening with TST or
QFT was much more
cost-effective in
contacts than
entering immigrants.
a) immigration entry
screening;
However, the
selection of screening
strategy is less
important than
program
performance.
Programs considering
these new ex vivo tests
for LTBI should thus
first ensure that a high
proportion of those
with positive tests will
be medically
evaluated, prescribed
and complete therapy.
b) close or
c) casual contacts.
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Table 1 Economic evaluations of latent tuberculosis infection screenings published up to July 2014 (Continued)
Hardy et al.
(UK; 2010)
[21]
1. NICE guidance 2006; Clinical trialc CEA Health care
payer
No Health
Direct
Cost per case LTBI
identified
Cost per case
identified:
QFT-first protocol can
be carried out more
cheaply than a CXR-
first protocol, with a
cost-saving of about
35% (£67.65)
compared to NICE
protocol. This saving
is due to the reduced
number of CXRs
required.
• NICE protocol: £160.81;
• Leed protocol: £93.16.
2. Leeds protocol: QTF
first in immigrants from
countries with TB
incidence >200/105
followed by CXR (all ages,
but mean age was 30.8
year).
Linas et al.
(USA; 2011)
[23]
1. TST; Published
literature
CEA,
CUA
Health care
payer
Markov
Lifetime
3.00%
Health
Direct
Nursing and physician
visits, diagnostic tests,
medications,
hospitalizations,
contact tracing, and
directly observed
therapy.
• Individuals at
highest risk of TB
reactivation (close
contacts and HIV-
infected) - ICER of
IGRA compared to
TST was <$100,000/
QALY gained.
In foreign-born
subjects IGRA was
cost-saving compared
to TST and cost-
effective compared to
no screening.
2. IGRA;
3. No LTBI screening.
Risk-groupsa
• The foreign-born -
IGRA was cost-saving
compared to TST and
cost-effective compared
to no screening (ICER
<$100,000/ QALY
gained).
• Vulnerable populations
(homeless, drug user,
former prisoner) - ICER
of TST screening was
approximately
$100,000-$150,000/
QALY gained, but IGRA
was not cost-effective.
• Medical co-morbidities
(diabetes and others) -
ICER of screening with
TST or IGRA was
>$100,000/QALY.
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Table 1 Economic evaluations of latent tuberculosis infection screenings published up to July 2014 (Continued)
Pareek et al.
(UK; 2011)
[15]
1. QFT; Clinical trialc CEA Government
health care
payer
Markov
20 years
3.50%
Direct UK NICE TB guidelines Screening of
immigrants from any
countries irrespective
of tuberculosis
incidence would cost:
• Screen immigrants
aged 16–35 years from
countries with
incidences/105
Screening for latent
infection can be
implemented cost-
effectively at a level of
incidence that
identifies most
immigrants with
latent tuberculosis,
thereby preventing
substantial numbers
of future cases of
active tuberculosis.
2. NICE guidance 2006b.
• QFT more than £1.5
million and prevent
44.5 cases of
tuberculosis;
≥250/105: £ 17,956
per case averted;
≥ 150/105: £ 20,819;
≥40/105: £ 29,403.
Screen immigrants
aged ≤35 years
irrespective of TB
incidence: £ 101,938.
• NICE guidance
≈£850,000 and
prevent 13.2 cases.
Pareek et al.
(UK; 2012)
[16]
1. TST+ in <35y
old immigrants;
Clinical trialc CEA Government
health care
payer
Markov
20 years
Direct Current UK national
guidance associated
with additional costs
of between £594,957
and £1,530,303 over
20 years.
• QFN (single):
£21,565 - £34,754 per
TB case averted.
Mandatory CXR on
arrival could be safely
eliminated in order to
improve screening
cost-effectiveness
with single-step QTF
at incidence threshold
>250/105 per year.
• CXR plus single QFN:
£59,489.
2. QTF+ in <35y
old immigrants;
• CXR plus single
T.SPOT.TB: £402,422.
3. T-SPOT+ in <35y
old immigrants.
All with or without CXR
port of entry.
Iqbal et al.
(USA, 2014) [22]
1. QFT; Administrative
data base
(2007)
CEA Government
health care
payer
Decision
model
Health
Direct
Screening, CXR,
Treatments, lab tests
and diagnostics,
physicians’ and staff
time.
Total screening cost:
TST US$38; QFT-G
US$74
Differential costs for
screening and follow-
up for subjects who
were estimated to be
test positive on 1,000
latent TB infections
QFT is cost-effective
especially for high-risk
populations such as
foreign-born
individuals.
2. TST.
Key assumption.
False positive rates:
• U.S. born• U.S. born
QFT: +US$25,037 vs.
TST.
TST 66%; QFT 40%
• Foreign born
Treatment duration: 9
months
QFT: −US$135,946.• Foreign born
TST 69%; QFT 18%
Treatment duration: 9
months
EE economic evaluation, ICER Incremental cost-effectiveness ratio, CEA cost-effectiveness analysis, CXR chest X-ray, CAN$ Canadian dollar, INH isoniazid, RIF rifampicin, PZM pyrazinamide, CUA cost-utility analysis, US$ United
States dollar, TST tuberculin skin test, QTF Quantiferon, QALY Quality Adjusted Life Years, CBA cost-benefit analysis, LTBI latent tuberculosis infection, TB tuberculosis, NICE National Institute for Health and Care Excellence, TB2
subjects with evidence of infection but no evidence of disease, TB4 subjects with stable radiographic abnormalities suggestive of TB together with evidence of TB infection and negative bacteriologic studies
a) Risk groups including recent immigrant adults and children, foreign-born residents living in the U.S. for more than five years (stratified by age), close contact adults and children, HIV-infected individuals, the
homeless, injection drug users, former prisoners, gastrectomy patients, underweight patients, and persons with silicosis, diabetes, and end-stage renal disease.
b) CXR in all immigrants from countries with TB incidence>40/105 and >16yo; TST if <16yo or <35yo from Sub Saharan Africa or from countries >500/105; QTF in TST positive to confirm LTBI.
c) Clinical trial description reported as Additional file 1: Table S2
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All evaluations complied with the following quality cri-
teria: presence of a clear hypothesis, methodology, selec-
tion of comparators, choice of appropriate benefits, and
local applicability. Only four evaluations referred to clin-
ical trials [15–17, 21], while medical evidence was de-
rived from published literature in the remaining 6
studies. Appropriate direct and indirect health costs were
considered in 8 assessments and sensitivity analysis was
performed in seven evaluations. The lower quality study
was the oldest [19]. Additional file 1: Table S1 presents
different assumptions concerning progression rate and
sensitivity as well as specificity of the TST and IGRAs ap-
plied in the different papers.
Economic evaluations of included studies
Cost-effectiveness analyses (CEA) were conducted in all
EEs, and only one cost-benefit analysis (CBA) [16]. Cost-
utility analysis (CUA) was performed in addition to CEA
in three EEs [18, 20, 23]. EEs were conducted under the
perspective of public health payer. Direct health costs
were assessed in all studies while indirect costs were con-
sidered in one study [18]. As shown in Additional file 1:
Table S2, four EEs were based on the results of specific
studies while the remaining 6 assessments were based on
available data in literature. Three studies [17, 20, 23] were
carried out prospectively for 12 to 31 months. Decision
modeling was adopted in 8 EEs with a time horizon up to
20 years [11, 15, 16, 19, 20] or lifetime [18, 23]. Data were
collected from studies carried out ad hoc in two EEs [20],
while models were fed with data publicly available in the
remaining 6 EEs.
Screening for LTBI in migrants was cost-effective ac-
cording to 8 studies [15–18, 20–23] and cost-saving
according the selected scenarios in 3 of these studies
[17, 18, 20]. In 5 out of 8 studies in which LTBI screen-
ing of migrants was cost-effective, a comparison between
single step IGRA and TST or TST plus confirmatory
IGRA was carried out [15, 16, 22–24]. In all 5 studies
one step IGRA was the most cost-effective strategy
(Quantiferon®, QTF in 4 studies [15, 16, 21, 22] and an
unspecified IGRA in the remaining study [23]). In the 2
studies in which LTBI screening strategy was not cost-
effective (dominated), the dominant strategies were con-
tact tracing investigations in one case [17], and screening
for active TB with CXR in the other case [11].
One article found that screening for LTBI with a single
step IGRA was cost-effective regardless of time since
immigration [23], while in other studies the cost-
effectiveness was evaluated in recent migrants only.
One study compared the cost-effectiveness of screening
stratified by age and showed that screening was more
cost-effective when addressing recent immigrant adults
than children and that screening of US foreign-born resi-
dents aged less than 45 years was more cost-effective than
screening of foreign-born residents aged 45–64 years [23].
In this study patient age affected cost-effectiveness results
through its impact on the lifetime risk of reactivation. In 3
other studies, in which LTBI screening was cost-effective,
the analysis was limited to children [17], or young adults
[15, 16].
Three studies compared the cost-effectiveness of
screening at different thresholds of TB incidence in the
country of origin. According to one study, the highest
cost-effectiveness was reached by screening immigrants
from countries with TB incidence above 200/100,000
while for two other studies, the threshold was 250/
100,000 [15, 16, 21].
One article provided information on which LTBI
treatment regimen (among isoniazid for 9 months, rifam-
picin for 4 months or rifampicin plus pyrazinamide for
2 months) would be more cost-effective according to mi-
grants country of origin showing that pyrazinamide plus
rifampicin for 2 months would be the most cost-effective
treatment for migrants from Vietnam, Philippines, and
Haiti, while isoniazid would be the most advantageous
regimen for other migrants [18].
Discussion
According to the majority of studies included in this
review, at least three important elements can be under-
lined. First, screening programs for detecting and treat-
ing LTBI in immigrants lead to substantial health and
economic benefits under a societal perspective. Second,
a one-step IGRA-protocol is the most cost-effective
strategy for LTBI screening in migrants. Third, targeting
young migrants from countries at higher incidence of
TB increases the cost-effectiveness of screening.
Limitations and possible biases should be considered.
First, our review, even if performed in a systematic
methodology, did not respect all the criteria for systematic
reviews (for example we consulted only two electronic
database) so we cannot make strong and quantitative con-
clusions. Secondly, we don’t know whether the LTBI
screening strategy that seems more cost-effective accord-
ing to the majority of the selected studies (the use of
IGRA) would be cost-effective in all context/jurisdiction,
as this heavily depends on the country-specific treatment
procedures and costs. Furthermore, we don’t have the
quality or quantitative weights of each study to be able to
make a pooled conclusion on cost-effectiveness. All these
issues can potentially be solved in a meta-analysis, that is
not attempted in this review given the high inhomogenei-
ties among the different studies included.
Additionally, all the selected studies included in the re-
view were carried out in countries were a CXR at entry
is currently performed for active TB screening of newly
arrived migrants. Most of the papers aimed at defining
cost-effectiveness of adding screening for LTBI to the
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ongoing CXR-based screening for active TB [15, 18–21, 23].
The cost-effectiveness of LTBI screening of migrants
population should also be evaluated in other low endemic
countries.
While most of the studies found that screening
programs for detecting and treating LTBI lead to sub-
stantial health and economic benefits under a societal
perspective, other studies reached opposite conclusions.
The importance of how methodological differences
affect results of EEs has been recently demonstrated in a
systematic review on methodological aspects of cost-
effective analysis of IGRAs for the diagnosis of LTBI
[24]. According to this study, some of the most relevant
contributing factors generating different conclusions are
the study inputs selection, the inconsistencies in the
costing approach, the utility of the QALY (Quality Ad-
justed Life Year) as the effectiveness outcome, and the
manner in which authors choose to present and interpret
study results.
Among the studies selected in our review, Oxlade O
et al. state that screening for active TB with CXR would
be the most cost-effective and QFT the least cost-
effective for screening of migrants on arrival [11], while
Pareek M et al. concluded that mandatory CXR on ar-
rival could be safely eliminated in order to improve
screening cost-effectiveness with single-step IGRA [16].
Opposite conclusions were reached because Oxlade O
et al. assumed a very low prevalence of LTBI in arriving
immigrants (0.08–2.1 %) [11], while Pareek M et al. as-
sumed a high rate of LTBI treatment completion (85 %
in case base scenario) [16].
Studies performed under program conditions have
shown that completion of LTBI treatment could be
much lower that what was assumed in the study pub-
lished by Pareek M et al. [16] with a better trend ob-
served when shorter and unsupervised regimen are used
[25]. It will be interesting to evaluate the completion
rate and cost-effectiveness of shorter regimen such as
weekly-administered rifapentine plus isoniazid for three
month [26, 27] in migrants.
In migrants the diagnostic delay in cases of active TB
is mainly related to the delayed presentation of the pa-
tients to the health system [28, 29] and it is responsible
for the spread of the disease among other members of
their community. Contact investigation should therefore
be strengthened in migrants, as well as in the general
population [30]. However, as assumed by the majority of
economic models reviewed, screening and treatment for
LTBI in migrants would prevent active TB cases and
solve the problem at its roots.
The reliability of Markov models, where time horizons
of 20 years or life time were used, may be matter of con-
cern. In fact, in most cases, modeling was based on pub-
lished or retrospective data while the prospective trials
supporting three EEs were all open label and only one
was controlled. The actual epidemiological data shows
that the global TB burden is reducing, though at a slow
pace, at global level [31], and in industrialized countries,
particularly among native populations [32]. In this sce-
nario, while the yield of the screening for LTBI will de-
crease over time, however the contribution to the
reduction of incidence by diagnosis and treatment of
LTBI will progressively increase.
Growing consensus indicates that progress in TB con-
trol in the low- and middle-income world will require
not only investment in strengthening TB control pro-
grams, diagnostics, and treatment but also action on the
social determinants of the disease [33]. To reduce the in-
cidence of TB, the drivers of the epidemic and social de-
terminants of TB need to be addressed. These include
co-morbidities, substance use, the social and economic
conditions that determine both the course of the TB epi-
demic and exposure to these risk factors [34]. This is
probably true for control of TB in migrants that often
live in disadvantaged socio-economic conditions in the
host country with an increased risk of both, to reactivate
LTBI or to acquire a new infection. In this perspective
LTBI screening and treatment in migrants could repre-
sent a synergistic tool to achieve the ambitious aim of
TB elimination.
Conclusions
The majority of the studies support the use of LTBI
screening strategies in migrants based on their cost-
effectiveness findings. When LTBI screening for mi-
grants are implemented they should focus especially on
young migrants from high incidence countries and effort
should be done to maximize the adherence to LTBI
treatment. In this view shorter LTBI treatment regimen
are preferred. Based on our review of EE analysis studies,
the use of one step IGRA is the best option in this par-
ticular setting. These findings should be confirmed by a
cost-effectiveness evaluation based on a medium-term
prospective study.
LTBI should be well integrated among the TB control
program for migrants and must be part of a wider ap-
proach with the aim of facilitating access of migrants to
the national health system, re-orienting health services,
improving the adhesion to anti-tuberculosis treatment in
cases of active TB, and promoting early diagnosis of active
TB cases by primary care health operators [35].
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